Abby Statler, PhD, MPH, discusses findings from an analysis of common clinical trial exclusion criteria and outcomes in clinical trials, which suggest that eligibility criteria should be “liberalized.”
Recent Articles
NIH Awards $1.5 Million for Fingerstick Hemophilia Test
The NIH has awarded $1.5 million to continue development of rHEALTH LLC’s fingerstick blood test for monitoring FVIII and emicizumab levels in hemophilia. The...
FDA Grants Venetoclax Combination Full Approval for Newly Diagnosed AML
Venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) has been FDA approved for the treatment of adult patients with newly diagnosed acute...
CDC Intelligence Officers Criticize U.S. Pandemic Response
In an open letter published on October 16, 2020, in the Epidemiology Monitor, 1,044 former and current officers of the U.S. Centers for Disease...
Gene Therapy for Hemophilia: Progress and Setbacks
As the FDA delayed the approval of the world’s first gene therapy for hemophilia A, companies forged ahead with phase III trials to gather...
Sequential Pembrolizumab and Chemotherapy Results in Excellent Responses in Newly Diagnosed Classical Hodgkin Lymphoma
A brief course of pembrolizumab monotherapy followed by AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) was associated with reductions in metabolic tumor volume and prolonged...
Current Issue
October 2020 Volume 6, Issue 12
This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.